[Stochastic risk estimation from medical x-ray diagnostic examinations (author's transl)].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to T Hashizume.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The in vitro activity of a new crystalline derivative of thienamycin, N-formimidoyl thienamycin (MK0787), was tested against 46 laboratory reference strains and 2,158 clinical isolates of gram-positive and -negative bacteria, including anaerobes, and compared with cefoxitin, cefaxolin, carbenicillin, and amikacin. MK0787 was significantly more active than the reference antibiotics against most bacteria tests. MK0787 was 16- to 500-fold more active than the other antibiotics against Staphylococcus aureus, Streptococcus pneumoniae, and group A and group B streptococci, inhibiting most isolates at concentrations less than 0.031 micrograms/ml. The inhibition concentration against over 90% of 156 strains of Streptococcus faecalis was 1 micrograms/ml. MK0787 had slightly less activity than carbenicillin against Haemophilus influenzae. The minimal inhibitory concentrations of MK0787 against strains of Enterobacter spp., Citrobacter spp., Serratia marcescems. Pseudomonas aeruginosa, and Clostridium difficile that are resistant to currently available antibiotics were less than or equal to 4 micrograms/ml. The only species found resistant to MK0787 was Pseudomonas maltophilia, which was equally nonsusceptible to the other reference antibiotics.
Explore the source record for details and available documents.
A novel synthesis of penta-deuterated 2-methylthiocytokinins, (+/-)-dihydrozeatin, and (+/-)-dihydrozeatin riboside is reported. penta-deuterated 2-methylthiocytokinins,2-methylthio-ribosyl-zeatin(I) and N6-isopentenyl-2-methylthioadenosine(II), were prepared by condensation of amines-d2 and 6-chloro-2-methylthio-9-beta-D-ribo-furanosylpurine-d3 which was derived from AICA-riboside. The deuterium contents of I and II were 95.75% and 98.27%, respectively. Racemic 4-hydroxy-3-methyl-l-butylamine-d5, which was prepared newly from gamma-butyrolactone, was condensed with 6-chloropurine and 6-chloro-9-beta-D-ribofuranosylpurine to give racemic dihydrozeatin (III) and dihydrozeatin riboside-d5 (IV). The deuterium contents were 97.82% and 97.23%, respectively.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.